Member Podcasts

The ASRS Member Podcast Series features on-demand audio discussions with retina leaders about research and advancements in technology, medicine, and treatment strategies that are enabling retina specialists to provide the best possible patient care.


Initial Results from the LADDER Trial

Carl C. Awh, MD, Tennessee Retina, Nashville, TN, discusses The LADDER Trial of the Port Delivery System with Ranibizumab: Initial Study Results with Updates from the Field reporter Andy Kalevar, MD.

Listen Now

DRCR.net Anti-VEGF Comparative Effectiveness Trial for Diabetic Macular

Edema

Neil Bressler, MD, Past Chair of the DRCR Network and Chair of its Education Committee, discusses clinical results of a DRCR.net analysis comparing 3 anti-VEGF treatments for diabetic macular edema in this DRCR.net audio abstract, sponsored by the National Eye Institute.


Financial disclosures

Dr. Bressler - GENENTECH/ROCHE: Investigator, Grants; NOVARTIS PHARMA AG: Investigator, Grants; REGENERGON PHARMACEUTICALS, INC.: Investigator, Grants; EMMES CORPORATION:  Investigator, Grants; BAYER:  Investigator, Grants; AMERICAN MEDICAL ASSOCIATION: Other, Grants; NORTHWESTERN UNIVERSITY:  Investigator, Grants.


Defining Vitreoretinal Interface Diseases

Jay S. Duker, MD

 
The International Vitreomacular Traction Study Group has helped establish new nomenclature for vitreoretinal interface diseases in order to address the lack of a cogent classification system for diseases of the vitreomacular interface.

In this interview, Netan Choudhry, MD, FRCS(C), Vitreous Retina Macula Specialists of Toronto, interviews study group lead investigator Jay S. Duker, MD, of New England Eye Center, about:

  • The group’s approach to developing the nomenclature
  • How ocriplasmin can be useful in the treatment of symptomatic vitreomacular adhesion (VMA) and small full-thickness macular holes
  • Why retina specialists’ understanding of the pathophysiology of vitreoretinal interface diseases continues to evolve

Listen now

 
Financial disclosures

Dr. Duker - ALCON LABORATORIES, INC: Consultant, Honoraria; ALLERGAN, INC: Consultant, Honoraria; CARL ZEISS MEDITEC: Other, Equipment (dept or practice); EMD/SERONO, INC: Consultant, Honoraria; EYENETRA: Stockholder, Stock; HEMERA BIOSCIENCES, INC: Founder, Stockholder, Stock; NOVARTIS: Consultant, Honoraria; OPHTHOTECH CORPORATION: Consultant, Stockholder, Honoraria, Stock; OPTOS PLC: Consultant, Honoraria; THROMBOGENICS, INC: Consultant, Honoraria.

Dr. Choudhry - ALLERGAN, INC: Advisory Board, Speaker, Honoraria; BAUSCH + LOMB, INC: Advisory Board, Honoraria; BAYER HEALTHCARE: Consultant, Speaker, Honoraria; NOVARTIS: Advisory Board, Speaker, Grants, Honoraria; OPTOS PLC: Speaker, Honoraria.


How Intraoperative OCT Systems May Improve Outcomes
 

Paul Hahn, MD, PhD

According to Paul Hahn, MD, PhD, of Duke Eye Center, intraoperative OCT systems are rapidly improving and may soon be in your operating room.

Dr. Hahn discusses this emerging technology with Netan Choudhry, MD, FRCS(C), and how its broad range of applications may improve surgical outcomes and possibly eliminate the need for intraoperative dyes or even surgical microscopes.

Listen now

 
Financial disclosures

Dr. Hahn - None.

Dr. Choudhry - ALLERGAN, INC: Advisory Board, Speaker, Honoraria; BAUSCH + LOMB, INC: Advisory Board, Honoraria; BAYER HEALTHCARE: Consultant, Speaker, Honoraria; NOVARTIS: Advisory Board, Speaker, Grants, Honoraria; OPTOS PLC: Speaker, Honoraria.
 


The Advent and Development of the Argus II Retinal Prosthesis System:
A Great Journey

Mark S. Humayun, MD, PhD

Mark S. Humayun, MD, PhD, of Keck School of Medicine/University of Southern California, sat down with Netan Choudhry, MD, FRCS(C), during the ASRS Annual Meeting in Toronto to discuss the advent and development of the Argus II Retinal Prosthesis System.

Listen to the interview to see why Dr. Humayun says of his work in developing this system, "It's been a great journey."

Listen now

 
Financial disclosures

Dr. Humayun – SECOND SIGHT MEDICAL PRODUCTS, INC: Consultant, Investigator, Intellectual Property Rights, Stock. 

Dr. Choudhry - ALLERGAN, INC: Advisory Board, Speaker, Honoraria; BAUSCH + LOMB, INC: Advisory Board, Honoraria; BAYER HEALTHCARE: Consultant, Speaker, Honoraria; NOVARTIS: Advisory Board, Speaker, Grants, Honoraria; OPTOS PLC: Speaker, Honoraria.


Imaging Pearls in AMD
 

Glenn J. Jaffe, MD

Netan Choudhry, MD, FRCS(C), and Glenn J. Jaffe, MD, of Duke University Medical Center, discuss imaging multimodal retinal imaging features and their prognostic value in age-related macular degeneration (AMD).

Listen now

 
Financial disclosures

Dr. Jaffe - HEIDELBERG ENGINEERING: Consultant, Honoraria; NEUROTECH: Consultant, Honoraria; PSIVIDA: Investigator, Grants

Dr. Choudhry - ALLERGAN, INC: Advisory Board, Speaker, Honoraria; BAUSCH + LOMB, INC: Advisory Board, Honoraria; BAYER HEALTHCARE: Consultant, Speaker, Honoraria; NOVARTIS: Advisory Board, Speaker, Grants, Honoraria; OPTOS PLC: Speaker, Honoraria.

Designed and built in Chicago by Webitects